Nab-Paclitaxel

Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,

Abstract

Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors.

Org: Pancreas Centre BC, Department of Pathology & Laboratory Medicine Vancouver General Hospital, British Columbia Cancer Research Centre, Providence Health - St. Paul's Hospital,

Abstract

Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Science and Peking Union Medical College,

Abstract

Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).

Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Cancer Center, Sun Yat-sen University, Guangzhou, China, Shantou Central Hospital, Shantou, China,

Abstract

Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.

Org: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.

Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, CHA University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA,

Abstract

Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma.

Org: The Affiliated Hospital of Guangdong Medical University,

Abstract

Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data.

Org: Department of Hematology, Oncology and Cancer Immunology, Medical Oncology Department-CHU Sart-Tilman, Department of Oncology. Experimental Cancer Therapy Unit, Hospital of LUHS Kauno Klinikos, Institute for Molecular Bioscience, The University of Queensland,

Abstract

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.

Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,

Abstract

Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases.

Org: City of Hope Comprehensive Cancer Center, Duarte, CA, CanSino Biologics,

Abstract

Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study.

Org: Imaging Department, Jiangsu Cancer Hospital Medical Oncology, Jiangsu Cancer Hopistal,

Abstract

Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.

Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,

Abstract

Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Org: Ramat Gan, Hadassah Hebrew - University Medical Center, Jerusalem, Medical Oncology and Immunotherapy, Siena,

Abstract

Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer.

Org: Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital,

Abstract

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, Guangdong, China,

Abstract

Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.

Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Fulgent Pharma,

Abstract

Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Org: Affiliated Zhenjiang Hospital of Jiangsu University, National Institute of Healthcare Data Science,

Abstract

Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

Org: Department of Pancreatobiliary Surgery,

Abstract

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).

Org: Epworth Medical Centre, New Zealand Clinical Research-Auckland, Rotorua Hospital, Blacktown Cancer and Haematology Centre, Beijing Tsinghua Changgung Hospital,

Abstract

FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study.

Org: Phase I Clinical Trials Center, The First Hospital of China Medical University,

Abstract

CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.

Org: Brown University/Lifespan Cancer Institute,

Abstract

GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Org: Chirurgia Digestiva, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Wallace McCain Center for Pancreatic Cancer,

Abstract

VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.

Org: Vall d´Hebrón Institute of Oncology (VHIO),

Abstract

A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.

Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,

Abstract

Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).

Org: Department of Quantitative Science Research, Mount Sinai Comprehensive Cancer Center, University of California, San Diego Moores Cancer Center, Inova Fairfax Medical Campus, Department of Medicine, Section of Hematology and Oncology, University of Chicago,

Abstract

Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.

Org: National Clinical Research Centre for Cancer,

Abstract

Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study.

Org: Fujian Normal University, Department of Breast Oncology, Fujian Cancer Hospital, Department of Oncology, Fujian Medical University Union Hospital, Department of Breast Medical Oncology, Fujian Cancer Hospital, Fuzhou University,

Abstract

Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial.

Org: Fujian Normal University,

Abstract

A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).

Org: Department of Thoracic Surgery and Lung Cancer Center, Pathologic Department,

Abstract

Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.

Org: 1440 Foundation,

Abstract

Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.

Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,

Abstract

A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).

Org: Clinical Research Alliance, LSU School of Medicine, CG Pharmaceuticals Inc.,

Abstract

Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Org: Atrium Health Wake Forest University Baptist Medical Center,

Abstract

J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.

Org: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan, Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan, Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Fukujuji Hospital, Tokyo, Japan, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan,

Abstract

Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,

Abstract

Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.

Org: Shangyu People's Hospital, Shaoxing, China,

Abstract

Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).

Org: Department of Respiratory Medicine, NHO Nagoya Medical Center,

Abstract

Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial.

Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,

Abstract

The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL).

Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,

Clinical trial

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Abstract

Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Org: Actuate Therapeutics, Inc., Courante Oncology,

Abstract

Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial.

Org: The Affifiliated Hospital of Qingdao University,

Abstract

Phase II trial of biologically optimized schedule of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer.

Org: The Ohio State University Comprehensive Cancer Center and Department of Internal Medicine, Center for Biostatistics, Department of Biomedical Informatics,

Abstract

Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.

Org: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China, The First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.

Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Gansu Provincial Cancer Hospital,

Abstract

Tislelizumab combined with nab-paclitaxel single-agent chemotherapy plus bevacizumab for patients with EGFR-TKIs-resistant advanced NSCLC with ECOG PS 0-2.

Org: National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health,

Abstract

A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.

Org: Zhengzhou University First Affiliated Hospital, Jiangsu Hengrui Pharmaceuticals Co.,Ltd,

Abstract

Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,

Abstract

Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).

Org: Virginia Mason Hospital and Medical Center, Verastem Oncology,

Abstract

ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.

Org: NewYork-Presbyterian/Weill Cornell Medical Center,

Abstract

Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.

Org: New York University, Grossman School of Medicine, New York University, School of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,

Abstract

Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer.

Org: BC Cancer-Vancouver Centre, Canadian Cancer Trials Group, Queen's University Belfast, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre,

Abstract

Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.

Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,

Abstract

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin as a first line treatment for the management of metastatic pancreatic adenocarcinoma: A budget impact analysis from a U.S. payer perspective.

Org: FIECON,

Abstract

Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as the first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC): An open-label, multicenter phase II trial– Updated results from AK104-IIT-014.

Org: Department of VIP Medical Services,

Abstract

Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP).

Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China,

Abstract

Nab-paclitaxel and gemcitabine (modified) in combination with oral cobimetinib and encorafenib following FOLFIRINOX in patients with metastatic G12D and G12V pancreatic cancer.

Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, Sylvester Cancer Center,

Abstract

Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

Org: Tiianjin,

Abstract

Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.

Org: The University of Tokyo, Tokyo, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, Shizuoka Cancer Center, Nagaizumi, Japan,

Abstract

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.

Org: Department of Oncology, Jiading Central Hospital, Shanghai, China, Department of Medical Oncology, Zhejiang Provincal People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China, Department of Oncology, Yancheng Third People's Hospital, Yancheng, China, Department of Oncology, Wuxi Branch of Ruijin Hospital, Wuxi, China, The Affiliated People’s Hospital of Ningbo University, Ningbo, China,

Abstract

4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.

Org: The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia, St. Vincent's Hospital, Darlinghurst, NSW, Australia,

Abstract

The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.

Org: Peking University Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,

Abstract

Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,

Abstract

A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.

Org: Fujian Cancer Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, West China Hospital, Union Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,

Abstract

Predictive value of baseline 68Ga‑FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC).

Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study.

Org: Guangdong Provincial People‘s Hospital,

Abstract

Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.

Org: Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China, Minimally Invasive Therapy Center, Shanghai Cancer Center, Fudan University, Shanghai, China, Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC).

Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China,

Abstract

Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study.

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, Zhejiang ACEA Pharmaceutical, China National Biotec Group,

Abstract

Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).

Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,

Abstract

First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting.

Org: Ipsen Biopharmaceuticals,

Abstract

Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.

Org: Shandong Academy of Medical Sciences,

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-21